News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
715,709 Results
Type
Article (42374)
Company Profile (436)
Press Release (672899)
Multimedia
Podcasts (80)
Webinars (13)
Section
Business (208774)
Career Advice (2022)
Deals (36011)
Drug Delivery (104)
Drug Development (83588)
Employer Resources (173)
FDA (16444)
Job Trends (15106)
News (352858)
Policy (33091)
Tag
Academia (2643)
Accelerated approval (6)
Adcomms (24)
Allergies (88)
Alliances (50975)
ALS (99)
Alzheimer's disease (1435)
Antibody-drug conjugate (ADC) (147)
Approvals (16425)
Artificial intelligence (278)
Autoimmune disease (26)
Automation (16)
Bankruptcy (372)
Best Places to Work (11841)
BIOSECURE Act (19)
Biosimilars (107)
Biotechnology (330)
Bladder cancer (83)
Brain cancer (27)
Breast cancer (299)
Cancer (2374)
Cardiovascular disease (191)
Career advice (1690)
Career pathing (30)
CAR-T (161)
Cell therapy (456)
Cervical cancer (20)
Clinical research (67870)
Collaboration (899)
Company closure (2)
Compensation (566)
Complete response letters (24)
COVID-19 (2650)
CRISPR (47)
C-suite (262)
Cystic fibrosis (106)
Data (2335)
Decentralized trials (2)
Denatured (29)
Depression (52)
Diabetes (280)
Diagnostics (6438)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (127)
Drug pricing (111)
Drug shortages (26)
Duchenne muscular dystrophy (103)
Earnings (88233)
Editorial (43)
Employer branding (21)
Employer resources (147)
Events (116199)
Executive appointments (758)
FDA (17828)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (802)
Gene editing (119)
Generative AI (20)
Gene therapy (337)
GLP-1 (756)
Government (4516)
Grass and pollen (4)
Guidances (150)
Healthcare (19150)
Huntington's disease (25)
IgA nephropathy (30)
Immunology and inflammation (136)
Indications (30)
Infectious disease (2797)
Inflammatory bowel disease (150)
Inflation Reduction Act (11)
Influenza (53)
Intellectual property (99)
Interviews (312)
IPO (16804)
IRA (43)
Job creations (3704)
Job search strategy (1434)
Kidney cancer (10)
Labor market (43)
Layoffs (506)
Leadership (18)
Legal (7987)
Liver cancer (77)
Lung cancer (332)
Lymphoma (158)
Machine learning (9)
Management (58)
Manufacturing (332)
MASH (76)
Medical device (13533)
Medtech (13538)
Mergers & acquisitions (19771)
Metabolic disorders (738)
Multiple sclerosis (84)
NASH (19)
Neurodegenerative disease (105)
Neuropsychiatric disorders (33)
Neuroscience (2021)
NextGen: Class of 2025 (6755)
Non-profit (4550)
Now hiring (40)
Obesity (394)
Opinion (223)
Ovarian cancer (82)
Pain (96)
Pancreatic cancer (89)
Parkinson's disease (157)
Partnered (21)
Patents (244)
Patient recruitment (116)
Peanut (47)
People (58728)
Pharmaceutical (86)
Pharmacy benefit managers (20)
Phase I (21326)
Phase II (29957)
Phase III (22136)
Pipeline (1369)
Policy (155)
Postmarket research (2601)
Preclinical (9155)
Press Release (67)
Prostate cancer (111)
Psychedelics (37)
Radiopharmaceuticals (263)
Rare diseases (409)
Real estate (6015)
Recruiting (66)
Regulatory (22791)
Reports (47)
Research institute (2416)
Resumes & cover letters (351)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (78)
Series A (141)
Series B (93)
Service/supplier (11)
Sickle cell disease (58)
Special edition (19)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3765)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (48)
The Weekly (49)
Vaccines (717)
Venture capitalists (44)
Weight loss (257)
Women's health (38)
Worklife (17)
Date
Last 7 days (950)
Last 30 days (3062)
Last 365 days (33353)
2025 (11992)
2024 (36301)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (736)
Alabama (59)
Alaska (7)
Arizona (241)
Arkansas (14)
Asia (39298)
Australia (6538)
California (6512)
Canada (2073)
China (547)
Colorado (278)
Connecticut (292)
Delaware (159)
Europe (85953)
Florida (950)
Georgia (213)
Idaho (57)
Illinois (565)
India (25)
Indiana (322)
Iowa (12)
Japan (173)
Kansas (109)
Kentucky (25)
Louisiana (12)
Maine (62)
Maryland (939)
Massachusetts (4923)
Michigan (225)
Minnesota (408)
Mississippi (2)
Missouri (82)
Montana (29)
Nebraska (25)
Nevada (67)
New Hampshire (67)
New Jersey (1821)
New Mexico (30)
New York (1820)
North Carolina (1054)
North Dakota (8)
Northern California (2838)
Ohio (211)
Oklahoma (14)
Oregon (38)
Pennsylvania (1435)
Puerto Rico (13)
Rhode Island (34)
South America (1111)
South Carolina (25)
South Dakota (1)
Southern California (2440)
Tennessee (105)
Texas (964)
United States (24488)
Utah (191)
Virginia (156)
Washington D.C. (66)
Washington State (585)
West Virginia (3)
Wisconsin (57)
715,709 Results for "nammi therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Nammi Therapeutics, Inc. Announces First Patient Dosed with QXL138AM in a Phase 1 Study Evaluating Advanced Solid Tumors and Multiple Myeloma
November 8, 2024
·
2 min read
Press Releases
Nammi Therapeutics, Inc. Completes Series B Round with Investment from MMRF’s Myeloma Investment Fund; Advances Clinical Development of Lead Program, QXL138AM
August 6, 2024
·
4 min read
Biotech Bay
Amgen and Biolabs LA at the Lundquist Institute Announce Nammi Therapeutics to Receive the Third Amgen Golden Ticket
Amgen and BioLabs LA at The Lundquist Institute announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticket in Southern California.
January 6, 2023
·
5 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Biotech Beach
Nammi Therapeutics Granted FDA Orphan Drug Designation For QXL138AM for the Treatment of Multiple Myeloma
Nammi Therapeutics, Inc. (Nammi), an LA-based immunotherapy company, announced today that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its lead program, QXL138AM, for the treatment of multiple myeloma.
June 13, 2022
·
2 min read
Press Releases
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
April 3, 2025
·
4 min read
Press Releases
Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update
April 30, 2025
·
8 min read
Press Releases
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025
May 7, 2025
·
5 min read
Policy
Nammi Therapeutics Granted FDA Orphan Drug Designation For QXL138AM for the Treatment of Pancreatic Cancer
Nammi Therapeutics, Inc., a Los Angeles based immunotherapy company, announced that the US Food and Drug Administration has granted orphan drug designation to its lead program, QXL138AM, for the treatment of Pancreatic Cancer.
June 16, 2022
·
2 min read
Press Releases
TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
March 26, 2025
·
4 min read
1 of 71,571
Next
